glecaprevir / pibrentasvir

Details

Generic Name:

Project Status:

Not filed

Therapeutic Area:

Hepatitis C, chronic

Manufacturer:

Pfizer Canada Inc.

Brand Name:

Maviret

Project Line:

Reimbursement Review

Project Number:

N/A

Manufacturer Requested Reimbursement Criteria¹:

CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer

Submission Type:

Non Submission

Indications:

Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients 3 years of age and older and weighing ≥ 12 kg.

Recommendation Type:

CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Last Updated : October 16, 2023